Panther Orthopedics announced successful clinical use of its PUMA™ flexible syndesmosis fixation device.
The Nitinol-based device is designed to offer stable dynamic fixation without postoperative creep or loss of fixation. "The spring-like design of the PUMA Body does the work to provide initial and continuous compression without the need to overtighten," said Kathy Stecco, M.D., CEO of Panther.
Panther Orthopedics received FDA 510(k) clearance to market PUMA in 1Q18, indicated for syndesmosis fixation, hallux valgus reconstruction and tarsometatarsal fixation. Founded in 2017, the company is backed by investment from Medeon Biodesign, a Taiwan-based incubator group.
Source: Panther Orthopedics, Inc.